Format

Send to

Choose Destination
Cochrane Database Syst Rev. 2001;(3):CD002883.

Domiciliary oxygen for interstitial lung disease.

Author information

1
Respiratory Unit, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, Australia, 5042. alan.crockett@flinders.edu.au

Abstract

BACKGROUND:

Retrospective survival data have suggested poor effectiveness of oxygen therapy in patients with interstitial lung disease (ILD).

OBJECTIVES:

To determine the effect of domiciliary oxygen therapy on survival and quality of life in patients with a diagnosis of ILD and hypoxaemia.

SEARCH STRATEGY:

Randomized Controlled Trials (RCTs) were identified using the Cochrane Airways Group register and the search terms: (home OR domiciliary AND oxygen AND (Interstitial lung disease OR ILD OR pulmonary fibrosis OR IPF)).

SELECTION CRITERIA:

Any randomized controlled trial (RCT) in adult patients with hypoxaemia and ILD that compared long term domiciliary or home oxygen therapy with a control group.

DATA COLLECTION AND ANALYSIS:

Only one unpublished RCT was identified.

MAIN RESULTS:

Only one trial was identified. Mortality for both the oxygen treated and control groups was approximately 91% after 3 years (Peto odds ratio 0.99, 95% confidence intervals 0.16,6.26). The effect of oxygen therapy on quality of life and physiological parameters was not reported.

REVIEWER'S CONCLUSIONS:

The assumption that home oxygen therapy has a beneficial survival effect in patients with ILD has not been demonstrated in the single RCT identified.

PMID:
11687030
DOI:
10.1002/14651858.CD002883
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center